Delta-Fly Pharma, Inc.
4598ＤｅｌｔａーＦｌｙ Ｐｈａｒｍａ株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-14For the first half of the fiscal year to 2026-03: Ordinary income ¥-0.8 billion, Net income ¥-0.8 billion.
| This period | Year on year | |
|---|---|---|
| Ordinary profit | −¥841m | — |
| Net profit to owners | −¥842m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4598/earnings-releases.
Financials
Japan GAAP · non-consolidated · fiscal year to 2026-03-31- Revenue
- —
- Net income
- −¥1.6bn
- ROE
- —
- Equity ratio
- 12.6%
- Dividend / share
- —
- Employees
- 12
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | — | −¥1,626m | ¥247m | ¥34m | — | ¥-140.45 | −¥1,557m |
| 2025-03-31 | — | −¥1,721m | ¥434m | ¥278m | — | ¥-195.58 | −¥1,835m |
| 2024-03-31 | — | −¥1,429m | ¥1,474m | ¥1,233m | — | ¥-198.78 | −¥1,280m |
| 2023-03-31 | — | −¥1,329m | ¥907m | ¥791m | — | ¥-234.51 | −¥1,303m |
| 2022-03-31 | ¥300m | −¥967m | ¥1,324m | ¥1,233m | — | ¥-178.58 | −¥940m |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | — | — |
| Equity ratio, % | 12.6 | 4.6 |
| Revenue growth | — | — |
| Net income growth | 0.0553 | 41.3 |
| Operating cash flow / assets | -6.3124 | 0 |
Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.
Via /v1/companies/4598/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4598/votingOwnership changes
All companies →- 2026-11-02
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 19.39% from 20.69%.
- 2026-11-02
Holdings of Evo Fund in Delta-Fly Pharma, Inc. (4598) moved below 20% (20.69% -> 19.39%).
- 2026-10-27
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 20.69% from 21.47%.
- 2026-10-21
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 21.47% from 22.55%.
- 2026-10-08
Evo Fund raised holdings in Delta-Fly Pharma, Inc. (4598) to 22.55% from 20.65%.
- 2026-10-07
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 20.65% from 22.71%.
- 2026-09-25
SBI SECURITIES Co.,Ltd. disclosed a 8.45% stake in Delta-Fly Pharma, Inc. (4598), crossing the 5% reporting threshold.
- 2026-09-16
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 22.71% from 32.11%.
- 2026-09-09
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 32.11% from 33.39%.
- 2026-09-08
Evo Fund reduced holdings in Delta-Fly Pharma, Inc. (4598) to 33.39% from 41.97%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Evo Fund | 2026-08-04 – 2026-10-26 | +4,212,600 | +17.31pt | ¥143.87 | ¥136–159 |
| Evolution Capital Management LLC | 2026-08-04 – 2026-10-26 | +4,212,600 | +17.31pt | ¥143.87 | ¥136–159 |
| アーカス・インベストメント・リミテッド | 2026-08-07 – 2026-09-04 | +455,000 | +3.09pt | — | — |
| マッコーリー バンク リミテッド | 2023-10-27 – 2026-07-27 | +9,172,200 | +75.93pt | ¥444 | ¥134–1,211 |
| 日本ケミファ株式会社 | 2023-11-10 – 2023-11-10 | +430,300 | +6.40pt | ¥1,162 | ¥1,162–1,162 |
| Macquarie Bank Limited | 2022-11-17 – 2023-01-20 | +1,300,000 | +19.35pt | ¥917.42 | ¥764–1,118 |
| individual filer | 2022-05-26 – 2022-05-26 | +32,000 | +0.58pt | ¥842 | ¥842–842 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4598/trades.
5% filings
Large shareholding reports on 4598| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-11-02 | Evo Fund | 19.39% | −1.30pt | pure investment |
| 2026-10-27 | Evo Fund | 20.69% | −0.78pt | pure investment |
| 2026-10-21 | Evo Fund | 21.47% | −1.08pt | pure investment |
| 2026-10-08 | Evo Fund | 22.55% | +1.90pt | pure investment |
| 2026-10-07 | Evo Fund | 20.65% | −2.06pt | pure investment |
| 2026-09-25 | SBI SECURITIES Co., Ltd. | 8.45% | — | — |
| 2026-09-16 | Evo Fund | 22.71% | −9.40pt | pure investment |
| 2026-09-09 | Evo Fund | 32.11% | −1.28pt | pure investment |
| 2026-09-08 | Evo Fund | 33.39% | −8.58pt | pure investment |
| 2026-09-08 | Arcus Investment Limited | 5.20% | — | control |
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| individual holder | 832,000 | 6.32% |
| BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD | 455,600 | 3.46% |
| 日本ケミファ株式会社 | 430,300 | 3.27% |
| individual holder | 358,600 | 2.72% |
| 楽天証券株式会社共有口 | 275,800 | 2.09% |
| individual holder | 260,000 | 1.97% |
| モルガン・スタンレーＭＵＦＧ証券株式会社 | 214,200 | 1.63% |
| MACQUARIE BANK LIMITED DBU AC | 174,900 | 1.33% |
| individual holder | 165,000 | 1.25% |
| 三洋化成工業株式会社 | 150,000 | 1.14% |
Get this as JSON
GET /v1/companies/4598
GET /v1/companies/4598/financials
GET /v1/companies/4598/details
GET /v1/companies/4598/segments
GET /v1/companies/4598/voting
GET /v1/companies/4598/tender-offers
GET /v1/companies/4598/indicators
GET /v1/companies/4598/earnings-releases
GET /v1/events?ticker=4598
GET /v1/companies/4598/trades
GET /v1/companies/4598/cross-holdings
GET /v1/companies/4598/brief